Mefloquine-Oxazolidine Derivatives: A New Class of Anticancer Agents

Felipe A. R. Rodrigues, Igor da S. Bomfim, Bruno C. Cavalcanti, Claudia Pessoa, Raoni S. B. Goncalves, James Lewis Wardell, Solange M. S. V. Wardell, Marcus V. N. de Souza*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

53 Citations (Scopus)


A series of 23 racemic mefloquine-oxazolidine derivatives, 4-[3-(aryl)hexahydro[1,3]oxazolo[3,4-a]pyridin-1-yl]-2,8-bis(trifluoromethyl)quinolines, derived from (R*, S*)-(+/-)-mefloquine and arenealdehydes, have been evaluated for their activity against four cancer cell lines (HCT-8, OVCAR-8, HL-60, and SF-295). Good cytotoxicities have been determined with IC50 values ranging from 0.59 to 4.79g/mL. In general compounds with aryl groups having strong electron-releasing substituents, such as HO and MeO, or electron-rich heteroaryl groups, for example imidazol-2-y-l, are active. However, other factors such as steric effects may play a role. As both the active and non-active conformations of the mefloquine-oxazolidine derivatives are similar, it is concluded that molecular conformations do not play a significant role either. This study is the first to evaluate mefloquine derivatives as antitumor agents. The mefloquine-oxazolidine derivatives are considered to be useful leads for the rational design of new antitumor agents.

Original languageEnglish
Pages (from-to)126-131
Number of pages6
JournalChemical biology & drug design
Issue number1
Early online date5 Oct 2013
Publication statusPublished - Jan 2014


  • anticancer
  • antitumor activity
  • mefloquine
  • oxazolidine
  • in-vitro
  • cell-death
  • autophagy


Dive into the research topics of 'Mefloquine-Oxazolidine Derivatives: A New Class of Anticancer Agents'. Together they form a unique fingerprint.

Cite this